Search

Author/Creator Li, Runzi

1. Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study. (15th December 2021)

Authors:
Mei, Heng; Liu, Xiaofan; Li, Yan; Zhou, Hu; Feng, Ying; Gao, Guangxun; Cheng, Peng; Huang, Ruibin; Yang, Linhua; Hu, Jianda; Hou, Ming; Yao, Yazhou; Liu, Li; Wang, Yi; Wu, Depei; Zhang, Liansheng; Zheng, Changcheng; Shen, Xuliang; Hu, Qi; Liu, Jing
Journal:
Journal of thrombosis and haemostasis
Issue:
Volume 20:Number 3(2022)
Page Start:
716
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study. (January 2022)

Authors:
Tang, Honghu; Cui, Beibei; Chen, Yiyu; Chen, Lin; Wang, Zhihong; Zhang, Ning; Yang, Yanlan; Wang, Xiaodong; Xie, Xiangliang; Sun, Lingyun; Dang, Wantai; Wang, Xianyang; Li, Runzi; Zou, Jianjun; Zhao, Yi; Liu, Yi
Journal:
Therapeutic advances in musculoskeletal disease
Issue:
Volume 14(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗